Project Grant R44AG077737
- Federal Project Grant Award Summary Hido Technologies, Inc. received a $1.24M Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on September 20, 2025, with completion targeted for May 31, 2027. The award funds Phase II development and validation of Homecare, an internet-connected self-medicating device integrated with a novel pharmacy distribution system (PDS) designed to improve medication adherence in patients with Alzheimer's disease and...
- VR-CARES Project Summary The National Institute on Aging (NIA) awarded Rendever, Inc. a Small Business Technology Transfer (STTR) Phase I project grant of $349,333 on May 1, 2025, under the Aging Research program (CFDA 93.866) to develop and test the feasibility of a virtual reality (VR) platform designed to support dementia caregivers. The VR-CARES (Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support) initiative builds upon Rendever's existing social engagement VR...
- This $2,497,615 federal Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), aims to evaluate the impact of new Medicare home health agency (HHA) payment policies on healthcare utilization and outcomes for Medicare beneficiaries with Alzheimer's disease and related dementias (ADRD). The project has three key objectives: 1) characterizing changes in the ADRD beneficiary population eligible for HHA services, 2) evaluating the effect of...
- This $1,933,556 Project Grant awarded by the National Institute on Aging (NIA) under its Aging Research program (CFDA 93.866) will support research to assess the impact of hospital-based health information technology (hospital-HIT) on healthcare quality and equity for patients with Alzheimer's disease and related dementias (ADRD). The primary awardee, the University of Maryland, College Park, will conduct a ten-year longitudinal study to evaluate how hospital-HIT systems that promote care...
- Federal Project Grant Award Summary Mentia DTX Inc. received a $505,561 Project Grant awarded on July 1, 2025, by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The award supports development of MentiaCompanion, an artificial intelligence-based virtual companion system designed to track changing health states in persons living with Alzheimer's disease and related dementias (ADRD). The solution addresses health inequities affecting the nation's 6.8 million...
- Federal Grant Award Summary On September 20, 2025, the National Institute on Aging awarded $999,372 to Dabble Health, Inc. under the Aging Research program (CFDA 93.866) to develop and validate Momento, an artificial intelligence-enhanced smartphone application designed for early detection of cognitive decline in older adults. The product leverages personalized photo-based games to continuously monitor brain health through user interactions while avoiding the anxiety and cultural biases...
- See Yourself Health LLC received a $612,981 project grant award from the National Institute on Aging, part of the Department of Health and Human Services, under the Aging Research program (CFDA 93.866). The grant funds the development of an immersive telehealth solution called the HOPE App, designed to deliver diabetes self-management education and support tailored for older adults with diabetes. The HOPE App will consist of 28 educational modules and maintenance programming delivered through...
- Federal Project Grant Award Summary The National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), awarded a $643,089 project grant to the University of Massachusetts Medical School to conduct an objective assessment of medication self-administration (MSA) as an early indicator of cognitive impairment and Alzheimer's disease and related dementias (ADRD). Commencing September 30, 2025, and concluding August 31, 2026, the research leverages the Framingham Heart Study cohort...
- Federal Grant Award Summary One Health Studio LLC received a $948,184 Project Grant from the National Institute on Aging (Aging Research Program, CFDA 93.866) awarded on September 20, 2025, to develop and evaluate the FLOURISH ALL platform, an artificial intelligence-enabled digital health solution designed to reduce Alzheimer's disease and related dementias (ADRD) risk in midlife women. The platform integrates an AI chatbot, wearable devices, and at-home biomarker collection kits to manage...
- Summary Johns Hopkins University received a $405,049 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded May 15, 2025, with a completion date of May 14, 2027. The grant funds development of an automated, reproducible, and updateable national longitudinal dataset documenting Medicaid Home- and Community-Based Services (HCBS) waiver characteristics extracted from waiver application documents. This dataset will be made publicly available to...
PREVENTING MEDICATION MISMANAGEMENT IN PEOPLE LIVING WITH DEMENTIA THROUGH AUTOMATED MEDICATION DISPENSING WITH FACIAL RECOGNITION AND VIDEO OBSERVATION - GLOBALLY, >47M INDIVIDUALS LIVE WITH DEMENTIA, WITH NEW INCIDENCE OF 7.7M ANNUALLY. MEDICATION MISMANAGEMENT IS ONE OF THE MOST COMMON AND CONCERNING RISK FACTORS IN PEOPLE WITH DEMENTIA (PWD), AS IT LEADS TO UNDERTREATMENT, EMERGENCY ROOM VISITS, HOSPITAL ADMISSIONS/READMISSIONS, AND SERIOUS ADVERSE EVENTS. 3M OLDER U.S. ADULTS ARE ADMITTED TO NURSING HOMES DUE TO DRUG-RELATED ADHERENCE PROBLEMS WITH COSTS >$14B/YEAR. FURTHERMORE, 30% OF HOSPITAL ADMISSIONS OF OLDER ADULTS ARE DRUG RELATED WITH 11% ATTRIBUTED TO MEDICATION NON-ADHERENCE AND 17% TO ADVERSE DRUG REACTIONS. WHILE ALZHEIMER'S DISEASE (AD) & TYPE 2 DIABETES MELLITUS (DM) INDIVIDUALLY HAVE CONSIDERABLE MORBIDITY & MORTALITY, THEY OFTEN OCCUR TOGETHER, WORSENING ADVERSE OUTCOMES, QUALITY OF LIFE, & CARE COSTS. THIS IS ESPECIALLY TRUE AS THE AD/DM COMBINATION CREATES A COMPLEX BALANCING ACT OF MED MANAGEMENT & SYMPTOM MONITORING IN OLDER POPULATIONS. WHILE THE GOAL IS TO KEEP OLDER ADULTS WITH DEMENTIA AT HOME AS LONG AS POSSIBLE, THESE CHALLENGES LEAD TO UNTOLD PERSONAL & FAMILY SUFFERING, AS WELL AS BILLIONS IN POTENTIALLY AVOIDABLE HEALTHCARE COSTS ANNUALLY. THE HIDO-ALZ PLATFORM WILL SOLVE THESE CHALLENGES BY AUTOMATING MEDICATION ADMINISTRATION FOR PWD TO ELIMINATE MISMANAGEMENT, DECREASE CAREGIVER BURDEN, REDUCE HEALTHCARE UTILIZATION, AND FACILITATE PWD TO AGE IN PLACE. HIDO IS BEING DEVELOPED AS AN AUTOMATED, AI DRIVEN MEDICATION DISPENSING AND DIRECT OBSERVATION PLATFORM TO OPTIMIZE ADHERENCE. THE DEVICE INTEGRATES MEDICATION DISPENSING, DOSE ADMINISTRATION TIME, MEDICATION SYNCHRONIZATION, & PAIR OF FRONT-FACING CAMERAS TO VALIDATE THE RIGHT MEDS, RIGHT ROUTE, RIGHT TIME, RIGHT DOSAGE TO THE RIGHT PATIENT (5R'S). CAMERAS RECORD EVERY DOSE USING FACIAL RECOGNITION & PROVIDE REAL-TIME MEDICATION CONSUMPTION RECORDINGS. THROUGH CLOUD CONNECTIVITY, PROVIDERS & CAREGIVERS HAVE ACCESS TO VIDEO OBSERVATION LOGS, DOSE ADMINISTRATION TIME, ADHERENCE TRENDS, & LONGITUDINAL ADHERENCE VIA WEB DASHBOARD. PATIENTS & CAREGIVERS CAN EASILY SETUP COMPLEX MEDICATION PROTOCOLS IN MINUTES USING A SMARTPHONE APP. THE DEVICE THEN ALERTS PATIENTS AND DISPENSES UP TO 7 DIFFERENT TYPES OF MEDS SIMULTANEOUSLY, WITH UP TO 90 DAYS OF MEDICATION. CONNECTED DATA SOURCES INCLUDING REMOTE BLOOD PRESSURE AND WEIGHT MEASUREMENTS, AS WELL AS ELECTRONIC HEALTH RECORD LAB RESULTS AND VIDEOCONFERENCING INTEGRATE IN A SINGLE DASHBOARD. THE PROJECT WILL BUILD ON SUCCESSFUL PHASE I, IN WHICH THE MEDICATION DISPENSING UNIT WAS UPDATED WITH MODIFICATIONS FOR DEMENTIA, PASSED ALL BENCH TESTING, AND WAS SUCCESSFULLY VALIDATED IN PILOT USABILITY WITH DEMENTIA SUBJECTS. PHASE II WILL EXPAND THE FOUNDATION WITH FOUR AIMS: 1) ENHANCE DEVICE WITH REMOTE SENSORS FOR DIABETES MANAGEMENT, EXPANDED DATA INTEGRATION, AND VIDEO CONFERENCING, 2) TEST ENHANCED PLATFORM FOR USABILITY IN DEMENTIA SUBJECTS, 3) TRANSITION THE DESIGN TO FORMAL MANUFACTURING PROCESS TO ENSURE SYSTEM MEETS PERFORMANCE STANDARDS AND REGULATORY REQUIREMENTS & PRODUCE PRE-PRODUCTION DEVICES FOR TESTING, & 4) CONDUCT IN-HOME CLINICAL TRIAL TO DEMONSTRATE ADHERENCE AND EFFICACY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.2m | 6/25/25 | ||
| Not listed | $0 | 12/31/24 | ||
| Not listed | $0 | 12/31/24 | ||
| Not listed | $0 | 11/5/24 | ||
| Not listed | $0 | 11/5/24 |